[{"NetIncomeLoss_1_Q2_USD":-55133000.0,"WeightedAverageNumberOfShareOutstandingBasicAndDiluted_1_Q2_shares":94326648.0,"CommitmentsAndContingencies_0_Q2_USD":null,"AccruedLiabilitiesCurrent_0_Q2_USD":25736000.0,"LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_0_Q2_USD":116254000.0,"AccumulatedOtherComprehensiveIncomeLossNetOfTax_0_Q2_USD":-86000.0,"RestrictedCashAndCashEquivalentsNoncurrent_0_Q2_USD":15227000.0,"NetCashProvidedByUsedInInvestingActivities_2_Q2_USD":-473260000.0,"PaymentsToAcquireInvestments_2_Q2_USD":629244000.0,"LesseeOperatingLeaseLiabilityPaymentsDueYearThree_0_Q2_USD":13378000.0,"AssetsCurrent_0_Q2_USD":713268000.0,"ContractWithCustomerAssetNetNoncurrent_0_Q2_USD":12264000.0,"WeightedAverageNumberOfShareOutstandingBasicAndDiluted_2_Q2_shares":93881734.0,"AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_2_Q2_shares":25100000.0,"StockIssuedDuringPeriodValueStockOptionsExercised_1_Q2_USD":3681000.0,"AccruedSalariesCurrent_0_Q2_USD":9913000.0,"LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_0_Q2_USD":12988000.0,"OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_2_Q2_USD":-156000.0,"OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_1_Q2_USD":174000.0,"CommonStockSharesIssued_0_Q2_shares":94265126.0,"Assets_0_Q2_USD":1015666000.0,"OperatingLeaseRightOfUseAsset_0_Q2_USD":66184000.0,"PreferredStockParOrStatedValuePerShare_0_Q2_USD":0.001,"ProceedsFromIssuanceOfCommonStock_2_Q2_USD":411766000.0,"CommonStockParOrStatedValuePerShare_0_Q2_USD":0.001,"AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_1_Q2_shares":25100000.0,"LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_0_Q2_USD":80825000.0,"GeneralAndAdministrativeExpense_1_Q2_USD":12168000.0,"OperatingLeaseLiability_0_Q2_USD":110473000.0,"IncreaseDecreaseInContractWithCustomerLiability_2_Q2_USD":-5208000.0,"LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_0_Q2_USD":7393000.0,"ResearchAndDevelopmentExpense_2_Q2_USD":92873000.0,"ResearchAndDevelopmentExpense_1_Q2_USD":48023000.0,"LesseeOperatingLeaseLiabilityPaymentsDue_0_Q2_USD":191298000.0,"OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCreditLossesOnDebtSecuritiesHeld_0_Q2_USD":0.0,"LettersOfCreditOutstandingAmount_0_Q2_USD":15200000.0,"OtherNonoperatingIncomeExpense_2_Q2_USD":-7233000.0,"OtherNonoperatingIncomeExpense_1_Q2_USD":-8354000.0,"AccountsReceivableNetCurrent_0_Q2_USD":10303000.0,"CommonStockValue_0_Q2_USD":94000.0,"GeneralAndAdministrativeExpense_2_Q2_USD":24668000.0,"IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_2_Q2_USD":9550000.0,"DepreciationDepletionAndAmortization_2_Q2_USD":2125000.0,"NetCashProvidedByUsedInFinancingActivities_2_Q2_USD":441769000.0,"FairValueAssetsLevel2ToLevel1TransfersAmount_0_Q2_USD":0.0,"DebtSecuritiesAvailableForSaleRealizedGainLoss_2_Q2_USD":0.0,"DebtSecuritiesAvailableForSaleRealizedGainLoss_1_Q2_USD":0.0,"OtherAssetsNoncurrent_0_Q2_USD":9000.0,"CashAndCashEquivalentsAtCarryingValue_0_Q2_USD":76654000.0,"OperatingLeaseLiabilityNoncurrent_0_Q2_USD":105405000.0,"ProceedsFromSaleMaturityAndCollectionsOfInvestments_2_Q2_USD":173584000.0,"CapitalizedContractCostAmortization_2_Q2_USD":1602000.0,"OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_1_Q2_USD":174000.0,"LesseeOperatingLeaseLiabilityPaymentsDueYearFive_0_Q2_USD":14193000.0,"LesseeOperatingLeaseLiabilityPaymentsDueYearFour_0_Q2_USD":13779000.0,"IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_2_Q2_USD":1669000.0,"FairValueAssetsLevel1ToLevel2TransfersAmount_0_Q2_USD":0.0,"AccretionAmortizationOfDiscountsAndPremiumsInvestments_2_Q2_USD":-2629000.0,"VariableLeaseCost_2_Q2_USD":591000.0,"VariableLeaseCost_1_Q2_USD":356000.0,"RetainedEarningsAccumulatedDeficit_0_Q2_USD":-657154000.0,"CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_2_Q2_USD":-90693000.0,"IncreaseDecreaseInAccountsReceivable_2_Q2_USD":4788000.0,"CommonStockSharesOutstanding_0_Q2_shares":94265126.0,"RestrictedCashNoncurrent_0_Q2_USD":15227000.0,"AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_1_Q2_USD":13254000.0,"NetCashProvidedByUsedInOperatingActivities_2_Q2_USD":-59202000.0,"LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_0_Q2_USD":13313000.0,"LongTermInvestments_0_Q2_USD":149501000.0,"LiabilitiesCurrent_0_Q2_USD":105600000.0,"PrepaidExpenseAndOtherAssetsCurrent_0_Q2_USD":7369000.0,"ProceedsFromStockOptionsExercised_2_Q2_USD":9323000.0,"OtherAccruedLiabilitiesCurrent_0_Q2_USD":7336000.0,"OperatingLeaseWeightedAverageDiscountRatePercent_0_Q2_pure":0.084,"ShortTermLeaseCost_2_Q2_USD":0.0,"ShortTermLeaseCost_1_Q2_USD":0.0,"AdditionalPaidInCapital_0_Q2_USD":1409214000.0,"CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_0_Q2_USD":91881000.0,"CapitalExpendituresIncurredButNotYetPaid_2_Q2_USD":1435000.0,"PropertyPlantAndEquipmentNet_0_Q2_USD":59213000.0,"NetIncomeLoss_2_Q2_USD":-100222000.0,"AccountsPayableCurrent_0_Q2_USD":5771000.0,"PaymentsToAcquirePropertyPlantAndEquipment_2_Q2_USD":17600000.0,"ContractWithCustomerLiabilityNoncurrent_0_Q2_USD":38925000.0,"StockholdersEquity_0_Q2_USD":752071000.0,"CommonStockSharesAuthorized_0_Q2_shares":250000000.0,"RevenueFromContractWithCustomerExcludingAssessedTax_2_Q2_USD":24552000.0,"RevenueFromContractWithCustomerExcludingAssessedTax_1_Q2_USD":13412000.0,"OperatingIncomeLoss_2_Q2_USD":-92989000.0,"OperatingIncomeLoss_1_Q2_USD":-46779000.0,"OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale_2_Q2_USD":0.0,"OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale_1_Q2_USD":0.0,"InvestmentIncomeInterest_2_Q2_USD":723000.0,"InvestmentIncomeInterest_1_Q2_USD":346000.0,"ContractWithCustomerLiabilityCurrent_0_Q2_USD":23032000.0,"PreferredStockValue_0_Q2_USD":3000.0,"OperatingLeaseCost_2_Q2_USD":7666000.0,"OperatingLeaseCost_1_Q2_USD":3897000.0,"LiabilitiesAndStockholdersEquity_0_Q2_USD":1015666000.0,"PreferredStockSharesAuthorized_0_Q2_shares":5000000.0,"AllocatedShareBasedCompensationExpense_2_Q2_USD":26230000.0,"AllocatedShareBasedCompensationExpense_1_Q2_USD":13254000.0,"SharePrice_0_Q2_USD":86.79,"OperatingLeaseLiabilityCurrent_0_Q2_USD":5068000.0,"OperatingExpenses_2_Q2_USD":117541000.0,"OperatingExpenses_1_Q2_USD":60191000.0,"RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_2_Q2_USD":1546000.0,"EarningsPerShareBasicAndDiluted_2_Q2_USD":-1.07,"EarningsPerShareBasicAndDiluted_1_Q2_USD":-0.58,"ProfitLoss_2_Q2_USD":-100222000.0,"ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_1_Q2_USD":-54959000.0,"ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_2_Q2_USD":-100378000.0,"Ticker":"FATE","CIK":"1434316","name":"FATE THERAPEUTICS INC","OfficialName":"Fate Therapeutics Inc. Common Stock","form":"10-Q","period":"20210630","fy":"2021.0","fp":"Q2","qtrs":"1","uom":"USD","footnote":"nan","Market Cap":"3545646272.0","Country":"United States","Sector":"Health Care","Industry":"Biotechnology: Biological Products (No Diagnostic Substances)","Market":"NASDAQ","SP500":"nan","filed":"20210804"}]